Immutep receives FDA Orphan Drug Designation for eftilagimod alfa in treating Soft Tissue Sarcoma, based on promising clinical trial results.
Quiver AI Summary
Immutep Limited announced that the FDA has granted Orphan Drug Designation to its treatment eftilagimod alfa for Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical needs. This designation supports the development of therapies for rare diseases and includes benefits such as regulatory support and market exclusivity upon approval. The decision comes after promising results from the Phase II EFTISARC-NEO trial, which showed a median tumor hyalinization/fibrosis of 51.5% in patients receiving efti alongside radiotherapy and KEYTRUDA, surpassing initial targets and historical figures for radiotherapy alone. Immutep's CEO highlighted the potential of efti for STS patients and noted that ongoing evaluations of the company's clinical strategy will influence future trials.
Potential Positives
- The FDA granted Orphan Drug Designation for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma, recognizing its potential therapeutic relevance in a rare cancer with significant unmet medical need.
- This designation may provide Immutep with regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval, which can enhance the company's competitive position.
- Encouraging clinical data from the Phase II EFTISARC-NEO trial supports the efficacy of efti in combination with radiotherapy and KEYTRUDA®, with results significantly exceeding pre-specified targets.
- The designation positions Immutep for potential advancement into a late-stage study in the neoadjuvant setting for STS, representing a strategic next step following recent trial evaluations.
Potential Negatives
- The press release acknowledges the ongoing review and analysis following the discontinuation of the Phase III TACTI-004 trial, indicating potential challenges and uncertainties in future clinical development.
- Despite the FDA's Orphan Drug Designation, the company is still in the early stages of developing eftilagimod alfa for soft tissue sarcoma, which may imply a lengthy and uncertain path to market.
- The statement does not outline any definitive plans or timelines for future trials, leaving investors without clear guidance on the progression of the product development.
FAQ
What is Orphan Drug Designation?
The Orphan Drug Designation is a status granted by the FDA to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the U.S.
What cancer is eftilagimod alfa being developed to treat?
Eftilagimod alfa is under development for the treatment of Soft Tissue Sarcoma (STS), a rare and difficult-to-treat cancer.
What were the results of the EFTISARC-NEO trial?
The EFTISARC-NEO trial showed a median tumor hyalinization/fibrosis of 51.5%, exceeding the target of 35% with radiotherapy alone.
What benefits does Orphan Drug Designation provide?
Benefits include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval.
Who should I contact for media inquiries regarding Immutep?
For media inquiries, contact Eleanor Pearson in Australia at +61 2 9066 4071 or email [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMP Hedge Fund Activity
We have seen 11 institutional investors add shares of $IMMP stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 243,097 shares (+41.9%) to their portfolio in Q4 2025, for an estimated $695,257
- SENDER CO & PARTNERS, INC. removed 215,861 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $617,362
- MORGAN STANLEY removed 159,394 shares (-96.0%) from their portfolio in Q4 2025, for an estimated $455,866
- TWO SIGMA INVESTMENTS, LP added 94,595 shares (+inf%) to their portfolio in Q4 2025, for an estimated $270,541
- MILLENNIUM MANAGEMENT LLC added 57,454 shares (+116.5%) to their portfolio in Q4 2025, for an estimated $164,318
- UBS GROUP AG added 45,324 shares (+180.6%) to their portfolio in Q4 2025, for an estimated $129,626
- CITADEL ADVISORS LLC removed 44,072 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $126,045
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMMP Price Targets
Multiple analysts have issued price targets for $IMMP recently. We have seen 2 analysts offer price targets for $IMMP in the last 6 months, with a median target of $5.5.
Here are some recent targets:
- Joel Beatty from Baird set a target price of $1.0 on 03/13/2026
- Reni J. Benjamin from Citizens set a target price of $10.0 on 02/23/2026
Full Release
SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for eftilagimod alfa (“efti”) for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.
The FDA’s Orphan Drug Designation program is designed to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States. Benefits of ODD may include regulatory support, potential tax credits, fee exemptions, and seven years of market exclusivity upon approval.
This designation recognises the potential therapeutic relevance of efti in STS, supported by encouraging clinical data from the investigator-initiated Phase II EFTISARC-NEO trial which has been evaluating efti in combination with radiotherapy and KEYTRUDA ® (pembrolizumab) in the neoadjuvant setting in patients with resectable soft tissue sarcoma. In 38 evaluable patients, the study met its primary endpoint, demonstrating a median tumour hyalinization/fibrosis of 51.5%, significantly exceeding the pre-specified target of 35% and historical benchmarks of ~15% with radiotherapy alone. 1
These results were observed across multiple sarcoma subtypes and were supported by translational data showing immune activation consistent with efti’s mechanism of action, with a favourable safety profile and no delays to planned surgery. 2
CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.”
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases
.
The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit
www.immutep.com
.
1. ESMO Congress 2025 Proffered Paper presentation, “EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma”.
2. CTOS 2025 Annual Meeting Oral Presentation, “Primary endpoint and translational correlates from EFTISARC-NEO: Phase II trial of neoadjuvant eftilagimod alfa (efti), pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma”.
KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071;
[email protected]
U.S. Investors/Media:
Matthew Beck, astr partners
Ph: +1 (917) 415-1750;
[email protected]
This announcement was authorised for release by the CEO of Immutep Limited.
